Earnings & Results

Omeros Beats Q3 Estimates as YARTEMLEA Sales Rise

OMEROmeros Corporation

Omeros reported third-quarter 2026 earnings of $0.06 per share, beating the consensus estimate of a loss of $0.05 per share and improving on a loss of $0.19 per share a year earlier. Sales of its transplant complication treatment YARTEMLEA rose year over year.

The company recorded a second consecutive quarter of positive operating cash flow, but a non-cash adjustment related to its convertible notes pushed it to a net loss for the period.

The quarter marks a swing from the company's recent full-year results: in fiscal 2025, Omeros reported a net loss of 3.4 million USD and diluted EPS of -0.05 USD.

Important questions to consider

Omeros posted quarterly earnings of $0.06 per share, while the consensus estimate had pointed to a loss of $0.05 per share. A year earlier, the company reported a loss of $0.19 per share.

Sources